This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Join Mailing List   |   Jobs   |   Print Page   |   Contact Us   |   Sign In   |   Join
News & Press: People and Places

PCORI Board Approves $15 Million for Project Led by ISTH Member Thomas Ortel

Friday, October 28, 2016   (0 Comments)
Share |

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors approved $14.8 million to fund a study led by ISTH member Thomas J. Ortel, titled: "Warfarin versus Direct Oral Anticoagulants for Secondary Prevention of Recurrent Venous Thromboembolism: A Randomized Comparative Effectiveness Trial." 

The project was organized by collaborators in the ISTH and CanVECTOR, including former ISTH Council Chairman Nigel Key.

The study will compare rivaraoxaban and apixaban against each other and against warfarin to see which works best in preventing the recurrence of dangerous blood clots in the veins and lungs. This randomized controlled trial will compare each drug’s safety and effectiveness in helping people who have suffered a potentially deadly blood clot and are at high risk for another.

>> Read more about the project

Membership Management Software Powered by YourMembership  ::  Legal